Genome-wide association study reveals the unique genetic structure of active blood donors

Jonna Clancy*[1], Jarkko Toivonen[1], Jouni Lauronen[1], Satu Koskela[1], Jukka Partanen[1], FinnGen[2], Mikko Arvas[1], Jarmo Ritari[1]

[1] Finnish Red Cross Blood Service, Vantaa, Finland

[2] List of FinnGen members is available as a supplementary file

* jonna.clancy@veripalvelu.fi

Abstract

The healthy donor effect (HDE) refers to the observed lower mortality rate among blood donors compared to the general population. While membership biases such as HDE arise due to healthier individuals being more likely to participate, the extent to which it is influenced by genetic differences remains largely unclear. To elucidate the genetic basis of HDE, we conducted a genome-wide association study (GWAS) involving 53,688 active blood donors with extensive donation histories and 228,060 controls from biobank cohorts within the FinnGen project. Our results identified 2,973 genome-wide significant loci associated with repeated blood donation and impacting several health-related endpoints and protein level alteration. Importantly, significant variants related not only to blood groups but also influenced the predisposition to somatic and mental diseases, suggesting that HDE is not solely tied to blood donation eligibility criteria. In conclusion, in this work we show that HDE is partially explained by genetic factors affecting various disease categories.

Keywords: blood donor, biobank, healthy donor effect, GWAS, blood group, HLA

Introduction

Blood donors play an important role as an excellent healthy control cohort in genetics and biomedical research due to their commitment and altruistic nature[1]. Their voluntary and frequent blood donations offer unique opportunities for longitudinal sampling. In addition, blood donors exhibit positive attitudes toward the use of their samples and data in scientific research, if not directly required in patient care[2,3].

However, blood donors are a highly selected population due to the health status criteria they must meet to be eligible to donate blood. Along with a general survey of the donor's current state of health, basic restrictions on blood donation suitability include serious illnesses such as severe cardiovascular conditions, cancer and epilepsy[4]. Some conditions that restrict blood donation suitability have strong well-known genetic background, such as the association of *HLA* genes in type 1 diabetes (T1D)[5] or in certain autoimmune diseases[6–8]. As a minimum hemoglobin level is required for donation eligibility, genetic variants affecting iron and hemoglobin levels may also cause donor selection. Due to these factors, blood donor selection results in a known phenomenon, *healthy donor effect*, HDE, which can lead to detrimental effects in a research setting if not taken into account[9].

Comprehensive selection of different blood groups, and especially a sufficient amount of emergency blood type O RhD neg suitable for most recipients, are basic requirements in blood banks. Due to the high need for emergency blood O RhD neg and strong immunogenicity of certain blood group antigens, such as ABO, Rh and Kell[10–13], donor recruitment is partially based on blood group genotype and results in enrichment of certain blood group antigens in a blood donor pool. Well known associations between ABO blood group antigens and cardiovascular conditions exist, more precisely between red cell antigen O and reduced thromboembolic diseases[14,15]. Risk for bleeding disorder, Von Willebrand disease, is known to be higher among individuals with red cell O antigen[16]. Pregnancy-induced hypertension has been previously described to occur more in RhD positive

individuals[15]. Moreover, in certain medical conditions, such as in hemochromatosis, blood donation

may be beneficial, and donors with these conditions may be enriched in the blood donor

population[17].

Enrichment of genetic variants with known disease associations or biological functions may result in

unpredicted effects in biomedical research. To reveal the genetic qualities of blood donors and to

understand the possible genetic selection leading to the HDE, we conducted a genome-wide

association study (GWAS) between the Finnish Red Cross Blood Service Biobank, and FinnGen (Figure

1). In addition, our aim was to discover genetic variants potentially contributing to personalized

blood donation and transfusion.

To our knowledge, no previous genome studies have focused on the possible selection bias caused

by blood group and health questionnaire-based requirement of blood donors. We found altogether

2,973 genome-wide significant associations. Genetic correlation analysis revealed strong negative

correlation between blood donorship and diseases such as mental disorders, pain disorders,

cardiovascular diseases, addiction disorders, autoimmune disorders, and Alzheimer's disease. *HLA*

association analysis confirmed the enrichment of hemochromatosis related *HLA* alleles and the

lower occurrence of autoimmune related *HLA* alleles in the blood donor population and indicated a

risk SNP tagging both hemochromatosis and autoimmune related *HLA* alleles. The genome-wide

significant variants associated with 112 plasma protein level alterations. The results of this study

demonstrate the genetic basis of the HDE, which is not limited to immediate blood donorship

inclusion criteria.

Figure 1 General workflow of the study. GWAS was performed on 53,688 cases (blood donors) and
228,060 controls. Genome wide significant GWAS results were fine-mapped and further used for
several association analyses. Genetic correlation of 2470 phenotypes to blood donorship were
calculated based on GWAS results. In addition, we imputed red cell antigens and tested their
association to blood donorship. Previously imputed HLA alleles in FinnGen project were used to
perform association analysis to blood donorship. Results of the previously performed protein
quantitative trait loci analysis were used to analyze the association of the fine-mapped variants to
protein level alteration. *Figure is created with BioRender.com.*

Results

Demographic information and differences in diagnoses between the two cohorts are described in

Table 1. In both sexes the blood donors were younger, taller and in males also heavier. More female

participants were seen in the blood donor cohort. A clear and significant difference between the two

cohorts was seen in both sexes in all the diagnose groups apart from ´XVI Certain conditions

89 originating in the perinatal period´ where more incidents were found among blood donors in both

90 sexes. FinnGen cohort consisted of donors in hospital biobanks but also donors in population cohorts

91 and in occupational health (Supplementary Table 1).

	Females		Males	
	Blood donors	FinnGen	Blood donors	FinnGen
Median age at sampling, years (IQR)	44.47 (18.2-70.8)	62.7 (36.2-89.2)	50.26 (25.5-75.0)	70.46 (51.3-89.6)
Sex, n (%)	32,460 (60.46)	120,279 (52.74)	21,228 (39.54)	107,781 (47.26)
Median weight, kg (IQR)	72 (54-90) [a]	72 (51-93) [a]	86 (68-104)	84 (64-104)
Median height, cm (IQR)	167 (159-175)	164 (156-172)	180 (171-189)	177 (168-186)
Median BMI (IQR)	25.83 (19.3-32.4)	26.64 (19.1-34.2)	26.58 (21.6-31.6)	26.88 (21.2-32.6)
FinnGen endpoint category [b]				
I Certain infectious and parasitic diseases (AB1)	7,466 (23)	47,901 (39.82)	5,565 (26.22)	48,487 (44.99)
II Neoplasms from cancer register (ICD-O-3)	968 (2.98)	34,299 (28.52)	791 (3.73)	38,891 (36.08)
II Neoplasms from hospital discharges (CD2)	6,960 (21.44)	67,026 (55.73)	2,804 (13.21)	52,708 (48.9)
III Blood and immune system (D3)	964 (2.97)	17,017 (14.15)	534 (2.52)	15,606 (14.48)
IV Endocrine, nutritional and metabolic (E4)	10,269 (31.64)	83,780 (69.65)	3,029 (14.27)	58,530 (54.3)
IX Circulatory system (I9)	6,276 (19.33)	69,429 (57.72)	4,587 (21.61)	78,876 (73.18)
V Mental and behavioural disorders (F5)	7,871 (24.25)	42,676 (35.48)	3,648 (17.18)	33,080 (30.69)
VI Nervous system (G6)	6,431 (19.81)	54,710 (45.49)	4,501 (21.2)	51,142 (47.45)
VII Eye and adnexa (H7)	8,088 (24.92)	58,567 (48.69)	4,660 (21.95)	47,174 (43.77)
VIII Ear and mastoid process (H8)	5,316 (16.38)	29,249 (24.32)	3,893 (18.34)	26,561 (24.64)
X Respiratory system (J10)	14,408 (44.39)	69,022 (57.38)	11,532 (54.32)	69,209 (64.21)
XI Digestive system (K11)	27,542 (84.85)	106,938 (88.91)	17,037 (80.26)	90,482 (83.95)
XII Skin and subcutaneous tissue (L12)	7,710 (23.75)	43,402 (36.08)	4,096 (19.3)	32,486 (30.14)
XIII Musculoskeletal and connective tissue (M13)	13,715 (42.25)	83,931 (69.78)	9,118 (42.95)	68,570 (63.62)
XIV Genitourinary system (N14)	17,334 (53.4)	91,665 (76.21)	4,463 (21.02)	49,729 (46.14)
XIX Injury, poisoning, external (ST19)	15,936 (49.09)	73,725 (61.29)	13,051 (61.48)	70,375 (65.29)
XV Pregnancy, childbirth and the puerperium (O15)	20,560 (63.34)	86,799 (72.16)	0 (0)	0 (0)
XVI Perinatal period (P16)	535 (1.65)	1,000 (0.83)	263 (1.24)	514 (0.48)
XVII Congenital malformations (Q17)	2,018 (6.22)	10,032 (8.34)	1,231 (5.8)	7,258 (6.73)
XVIII Abnormal clinical and laboratory findings (R18)	16,800 (51.76)	93,458 (77.7)	9,125 (42.99)	80,419 (74.61)
XX External causes of mortality (VWXY20)	13,025 (40.13)	64,874 (53.94)	10,741 (50.6)	62,034 (57.56)
XXI Contact with health services (Z21)	24,581 (75.73)	10,4068 (86.52)	10,544 (49.67)	72,915 (67.65)
XXII Codes for special purposes (U22)	1,417 (4.37)	5,906 (4.91)	595 (2.8)	4,310 (4)

[a] Not significant
[b] Shortened for clarity

94 Table 1 Demographic information of the cohorts. Age, sex, height, weight, BMI and FinnGen
95 endpoint categories in blood donors and FinnGen cohort are shown. Apart from weight in females,
96 difference between the cohorts in each phenotype was statistically significant.
97

Genome-wide association analysis

Genome-wide association analysis revealed 2,973 significant (p < 5x10^{-8}) genetic loci associated with

blood donorship. After fine-mapping, 5 coding (4 missense and 1 inframe deletion) and 36 non-

coding variants were detected (Figure 2A). In addition to these 41 variants, 5 non-coding lead

variants in the extended MHC region (Figure 2B and C) were included in the downstream analyses

(Table 2).

The strongest genome-wide associations were seen in variants related to blood group antigens:

rs55794721, p = 8.88x10^{-89}, in chromosome 1, rs687621, p = 5.70x10^{-81}, in chromosome 9 in *ABO*

gene and rs8176058, p = 1.16x10^{-31}, in chromosome 7 in *KEL* gene (Figure 1A, Table 2).

Despite of the adjustment of the GWAS for BMI, we observed significant GWAS variants known to

influence height, weight, and BMI. rs66781921, an inframe deletion variant in chr2, previously

shown to have a negative association to height, weight and body mass index[18], was rarer in blood

donors (beta = -1.97, p = 1.89 x 10^{-11}). Missense variant rs34811474, previously shown to be

negatively associated with body mass index[18], was seen to be more frequent in blood donors (beta =

0.064, p = 1.21 x 10^{-12}). Variants rs10947114 (p = 2.88 x 10^{-09}, beta = -0.055), rs3130906 (p = 5.17 x

10^{-11}, beta = -0.055) and rs4713637 (p = 1.39 x 10^{-08}, beta = -0.047), previously described to be

associated with spondylopathies and celiac disease[18], were negatively associated with blood

donorship. A rare intron variant, rs528492111, in chromosome 3 previously shown to have a weak

association to benign neoplasm of conjunctiva[18], was more frequent in blood donors (beta = 1.87, p

= 4.09 x 10^{-10}).

All the fine-mapped and MHC lead variants in the are listed in Table 2.

Figure 2 A) Manhattan plot of the genome-wide association study of blood donorship. B) Extended
MHC region of the chromosome 6 of the GWAS. C) Chromosome 6 association study adjusted for
type 1 diabetes, T1D. Red dot indicates fine-mapped variants in panel A and in panels B and C the
highest variant in each peak reaching the genome wide significance, $<5 \times 10^{-8}$. The name of the
nearest gene is shown for these variants if the p-value is $\leq 5 \times 10^{-9}$. The horizontal line has been set to
5×10^{-8}.

	Genome wide association study					pQTL
rs ID	p-value	Beta	Effect	Target gene	Nearest	Target protein
rs66781921	1,89E-11	-1,973	inframe deletion	NCL	SNORD82	-
rs1135071	2,93E-13	-0,573	missense	HBB	HBB	AHSP
rs199598395	1,55E-25	-0,383	missense	RNF43	SUPT4H1	FTL, HAMP, FGF23
rs8176058	1,16E-31	-0,327	missense	KEL	KEL	KEL
rs191302298	3,89E-08	-0,292	intron	LINC01411	MSX2	-
rs10096658	1,35E-08	-0,277	intron	ZFPM2	LRP12	-
rs62113181	8,06E-09	-0,135	intron	KDM4B	KDM4B	-
rs75738358	4,89E-08	-0,080	intergenic	NA	MIR4801	-
rs12539059	5,68E-09	-0,071	downstream gene	COL26A1	LINC01007	KLK11
rs9272324	1,36E-16	-0,064	intron		HLA-DQA1	HERC5, METTL2B, MICB, HLA-DRA, ==C4B*==
rs36035346	5,48E-09	-0,062	intron	CRTC1	CRTC1	-
rs60678519	1,06E-08	-0,055	downstream gene	AC079780,1	RPS2P32	GPNMB
rs10947114	2,88E-09	-0,055	intron		SFTA2	DDR1
rs3130906	5,17E-11	-0,055	intron		HCP5	MICA, CDSN, MICB
rs80319585	1,92E-08	-0,055	intron	KCNMA1	KCNMA1	-
rs7795945	1,28E-09	-0,049	intron	PCLO	PCLO	-
rs34483988	1,65E-08	-0,049	intron	FAM171B	FAM171B	-
rs6775319	2,17E-09	-0,048	intron	SATB1-AS1	SATB1	-
rs7907026	4,63E-10	-0,048	intergenic	NA	SORCS3	-
rs3806234	5,16E-09	-0,047	upstream gene	SNAPIN	SNAPIN	-
rs4713637	1,39E-08	-0,047	intergenic		LINC00336	-
rs62083414	5,35E-09	-0,046	intron	DCC	DCC	-
rs207350	3,03E-08	-0,045	intergenic	NA	LCORL	-
rs594398	1,18E-08	-0,044	intron	SUMO2P17	ATP5G1	-
rs10880819	2,64E-08	0,043	downstream gene	RF00019	ALG10B	-
rs35440643	4,54E-08	0,044	intron	ZNF638	ZNF638	-
rs10166897	1,57E-08	0,044	intron	MAPRE3	MAPRE3	CGREF1
rs113236240	6,53E-09	0,045	intron	PPCDC	PPCDC	MPI, PPCDC
rs55763604	2,84E-08	0,049	intron	BNC2	BNC2	-
rs55732343	2,31E-10	0,049	regulatory region	NA	SLC9A1	-
rs9968910	1,12E-09	0,050	intergenic	NA	HIST1H1C	-
rs5821444	7,98E-09	0,051	3 prime UTR	C17orf58	C17orf58	-
rs6498415	5,47E-10	0,053	intron	U91319,1	SHISA9	-
rs12444334	1,51E-09	0,053	intron	GAS8	C16orf3	CDH15
rs11675100	3,88E-09	0,054	intron	AC007100,1	MIR4432	-
rs9367942	3,81E-08	0,055	intron	STMND1	STMND1	-
rs61937595	1,25E-08	0,062	intron	R3HDM2	R3HDM2	INHBC
rs34811474	1,21E-12	0,064	missense	ANAPC4	ANAPC4	-
rs1500956	5,14E-10	0,075	intron	PDE4B	PDE4B	-
rs77448558	1,28E-08	0,078	intergenic	NA	GRIK2	-
rs10268629	1,71E-09	0,078	intergenic	NA	TAC1	-
rs75350584	1,58E-08	0,094	intron	DLEU1	ST13P4	-
rs687621	5,70E-81	0,147	intron	ABO	ABO	63 different
rs55794721	8,88E-89	0,157	upstream gene	SYF2	SYF2	ICAM4
rs118101548	1,90E-08	0,299	intron	POLD1	POLD1	-
rs528492111	4,09E-10	1,875	intron	WDR6	WDR6	-

Table 2. Fine-mapped and MHC lead variants. Significance, effect size, the most serious effect and
nearest gene for each variant is shown. If the variant was associated with altering protein expression
levels, the target proteins are shown.

Genetic correlation

Altogether 593 phenotypes were negatively correlated with blood donorship (FDR < 0.05,

Supplementary file 2). Height was the only phenotype showing weak positive correlation with blood

donorship, r_g = 0.07 (Figure 3A) despite the GWAS having been adjusted for BMI. Phenotypes

associated with some of the individual variants detected by the GWAS with a relatively strong effect

size did not show strong correlation with blood donorship. In turn, some phenotypes associated with

individual variants with small effect size in GWAS were relatively strongly correlated to blood

donorship (Figure 3B).

Blood donorship was negatively correlated with r_g < -0.5 to 30 phenotypes (Supplementary file 2).

The strongest negative correlation (r_g < -0.6) in blood donors was seen with Anemias (r_g = -0.66, FDR

= 2.81 x 10^{-112}), 'Other reaction to severe stress and adjustment disorders' (r_g = -0.64, FDR = 3.36 x

10^{-40}) and 'Other disorders of teeth and supporting structures' (r_g = -0.62, FDR = 2.74x10^{-03}).

Furthermore, negative correlation was observed in phenotypes such as autoimmune diseases (r_g = -

0.33, FDR = 1.87 x 10^{-52}), cardiovascular diseases (excluding rheumatic etc) (r_g = -0.42, FDR = 3.79 x

10^{-64}) and bleeding disorders (r_g = -0.39, largest FDR = 7.10 x 10^{-11}) (Figure 3C). In addition, negative

correlation to blood donorship was observed in phenotypes such as addiction disorders (r_g = -0.33,

largest FDR = 7.09 x 10^{-04}), pain disorders (r_g = -0.45, largest FDR = 1.41 x 10^{-10}) and Alzheimer's

disease (r_g = -0.24, FDR = 0.03) which are not directly restricted by blood donation eligibility criteria,

but which undeniably effect on donation suitability or donor's knowledge on their current state of

health. Another example of phenotypes not directly restricted by blood donation eligibility but with

relatively strong negative correlation towards blood donorship are infectious phenotypes, such as

acute bronchitis (r_g = -0.58, FDR = 1.76 x 10^{-16}) and 'other or unspecified bacterial infection' (r_g = -

0.50, FDR = 1.83 x 10^{-09}) (Figure 3A, Supplementary file 2). Furthermore, protective negative

correlation with viral hepatitis was observed among blood donors (r_g = -0.51, FDR = 1.88 x 10^{-07}).

Although blood-borne viral diseases are an obstacle to blood donation, it is not assumed that the

blood donor population has a protective inheritance against these viral diseases.

Figure 3. Genetic correlation of blood donorship to 594 phenotypes. A) Genetic correlation of 40
phenotypes representing the strongest negative and strongest positive correlation to blood
donorship. B) For each of the 46 variants and their most significantly associated FinnGen phenotypes
the effect size of the variant and the genetic correlation of the phenotype to blood donorship is
shown. The phenotype is labeled when the absolute value of the effect size is higher than 0.25.
The vertical bars indicate the standard error of the genetic correlation estimate. C) Genetic
correlation matrix of selected phenotypes. Pain disorders, mental disorders, bleeding disorders and
addiction disorders have been grouped from several phenotypes belonging to same phenotype
category and average genetic correlation is shown. This results in some of the diagonal elements
being less than one.

Blood group antigen related associations

To understand whether blood donor selection leads to enrichment of blood groups in the blood

donors, we evaluated the association of imputed red cell antigens with blood donorship using a

logistic regression model. The model revealed a strong negative association for blood group antigens

Kell, RhD, and AB and a positive association for blood group antigen O (Figure 4A). Results of the

GWAS covariates and red cell antigens are available in Supplementary file 2.

We further analyzed the blood group related significant GWAS variants in chromosomes 1, 7 and 9

with linear regression models. Lead variant in chromosome 1, rs55794721, was associated with the

Rh blood group system (previously shown to be associated with height[18]). Rh antigens E, C and D

were negatively associated with rs55794721, whereas e and c antigens of the most common Rh

negative haplotype in the Caucasoid population, dce[11], were positively associated with rs55794721

(Figure 4B). 91% of individuals that were positive for Rh c and e alleles and had no Rh D, C or E

alleles, were homozygotes (dosage value > 1.5) for rs55794721. rs55794721 is in LD[19] (R^2 = 0.39) with

variant rs586178 tagging certain RhCE blood group alleles[20]. Lead variant in chromosome 7,

rs8176058, a known tag SNP for Kell blood group antigen[20] was positively associated with K antigen

(Figure 4C). Lead variant in chromosome 9, rs687621[19], is in strong LD, R^2 = 1 with blood group O

tagging SNP rs687289[21]. We could also see a strong positive association of rs687621 with blood

group antigen O, a positive association with blood group antigen B and a negative association with

blood group antigen AB (Figure 4D).

Figure 4 Association of blood group antigens with blood donorship, rs55794721, rs8176058 and rs687621. Blood group antigens K, Dob, D and AB were negatively, and blood group antigen O positively associated to blood donorship. Blood group antigens c and e, belonging to the most common Rh-negative haplotype Rh dce, were positively associated to rs55794721, whereas blood group antigens D, C and E were negatively associated with rs55794721. Blood group antigens Cw and Cx were negatively associated with rs55794721. Blood group antigen K was positively associated with rs8176058. Blood group antigens O and B were positively associated and blood group antigen AB negatively associated with rs687621 in ABO gene.

Hemoglobin related associations

As hemoglobin value within a specified interval is a required for blood donation eligibility, we

investigated whether some of the genome-wide significant variants were associated with

hemoglobin. Hemoglobin-related associations were seen in chromosomes 6, 9, 11 and 17 in variants

rs9968910, rs3130906, rs687621, rs1135071 and rs199598395, respectively (Supplementary Figure

2). We observed a negative association between rs199598395 in RNF43 gene in chromosome 17 and

blood donorship. rs199598395 has been previously shown to be Finnish enriched and associated

with iron deficiency anemia[22] and to have an effect on blood donation eligibility[23]. Negative

association in blood donorship was also seen with rs1135071 in chromosome 11, in a known Finnish

enriched Hb variant, Hb Tacoma[24], in HBB gene. Linear regression analysis of blood service

operational finger-prick Hb measurements showed a decreasing effect of rs199598395, rs1135071

and rs3130906 to hemoglobin level -2.99 g/L (p = 6.43 x 10^{-30}, 95% CI [-3.49, -2.5]), -6.46 g/L (p = 6.66

x 10^{-28}, 95% CI [-7.57, -5.35]) and -0.22 g/L (p = 0.002, 95% CI [-0.32, -0.11]) respectively, and

moderate increasing effect of rs9968910 and rs687621, 0.52 g/L (p = 4.03 x 10^{-22}, 95% CI [0.42-0.62])

and to 0.25 g/L (p = 1.72 x 10^{-05}, 95% CI [0.15-0.35]), respectively (Supplementary file 2). In summary,

all the alleles of these five variants that had an increasing effect on hemoglobin, were more frequent

in blood donors (Table 2).

We detected a higher allele frequency, 0.69, of rs9968910, previously shown to be associated with

diseases of iron metabolism[18], among patients with clinical hereditary hemochromatosis (ICD10 code

E83.1) in FinnGen (N=477) compared to population level frequency in Finland, 0.33[25]. rs9968910 is in

weak LD with known HFE mutations causing hemochromatosis: rs1799945 (H63D, R^2 = 0.18) and

rs1800562 (C282Y, R^2 = 0.1)[19].

Association of the *HLA* alleles

Because of the known strong role of the HLA region in immunology and the predisposing risk of

certain HLA alleles in autoimmunity[5–8,26], we performed an association study with imputed HLA

alleles for blood donor endpoint. We could see a strong association (p = 1.36 x 10^{-16}) with rs9272324

in chromosome 6 in *HLA-DQA1* gene in the genome-wide association study of blood donorship

(Figure 1B). However, after adjusting with T1D (ICD10 E10 and ICD9 250), no significant association

in *HLA-DQA1* gene was seen (Figure 1C). *HLA* association analysis for the blood donor phenotype

(Figure 5, upper panel) revealed negative association with *HLA*-alleles in linkage with the well-known

T1D risk genotype *HLA-DQ2/DQ8*. *HLA* haplotypes *DRB1*03:01-DRB3*01:01-DQA1*05:01-*

*HLADQB1*02:01* and *DRB1*04:01- DRB4*01:03- DQA1*03:01- DQB1*03:02* are known to occur with

HLA-DQ2 and HLA-DQ8, respectively. The *HLA* alleles in linkage with *HLA-DQ8* were negatively

associated with blood donorship: *DRB1*04:01* (beta = -0.12, FDR = 2.2 x 10^{-11}), *DRB4*01:03* (beta = -

0.06, FDR = 2.75 x 10^{-8}), *DQA1*03:01* (beta = - 0.09, FDR = 1.16 x 10^{8}) and *DQB1*03:02* (beta = -0.09,

FDR = 9.99 x 10^{-9}). HLA-alleles previously shown to be associated with *HFE C282Y* allele in Finland[17]

or class II alleles with known protection from T1D[27], *B*07:02* (beta = 0.07, FDR = 5.45e-10^{5}),

*DRB1*15:01* (beta = 0.06, FDR = 5.45 x 10^{-5}), *DQA1*01:02* (beta = 0.05, FDR = 5.45 x -10^{-5}) and

*DQB1*06:02* (beta = 0.06, FDR = 9.24 x -10^{-5}) were positively associated with blood donorship. *HLA-*

*DRB5*01:01* (beta = 0.06, FDR = 5.45 x 10^{-5}) and *HLA-DPB1*05:01* (beta = 0.1, FDR = 0.04) were

positively associated with blood donorship. These two alleles are known to TÄHÄN FREK 0.000111

Furthermore, *HLA-B*27:05* (beta = -0.07, FDR = 1.96 x 10^{-3}), a well-known ankylosing spondylitis risk

allele[26], was negatively associated with blood donorship. Adjustment with chr6 lead variant,

rs9272324 (Figure 5, middle panel), decreased the effect sizes and increased p-values of the above-

mentioned *HLA* alleles in linkage with *HLA-DQ8* and *HLA-B*27:05* and increased the p-values of the

above mentioned HFE C282Y related *HLA*-alleles above the significance level (Supplementary file 2).

Furthermore, when adjusted with the lead *HLA*-allele, *DRB1*04:01* (Figure 5, lower panel), *HLA-*

*B*27:05* (beta = -0.08, FDR = 2.84 x 10^{-04}) and *HLA-C*02:02* (beta = -0.06, FDR = 2.95 x 10^{-02}) in LD (r^2

= 0.3) with *HLA-B*27:05*, HLA-alleles in linkage with the T1D risk genotype *HLA-DQ2; DRB1*03:01*

(beta = -0.05, FDR = 4.31 x 10^{-03}), *DQA1*05:01* (beta = -0.06, FDR = 2.45 x 10^{-03}), *DQB1*02:01* (beta =

-0.06, FDR = 4.31 x 10^{-03}) and *HLA-B*08:01* (beta = -0.05, FDR = 4.2 x 10^{-02}), a known *HLA-B* allele in in

linkage with *HLA-DQ2* in Finland, were negatively associated with blood donorship (Figure 4, lower

panel). In *HLA-DRB1*04:01* adjusted analysis, HFE C282Y related *HLA* alleles *B*07:02*, *DRB1*15:01*,

DQA1*01:02 and *DQB1*06:02* were positively associated with blood donorship, but with lower p-

values than in *HLA*-association analysis without any adjustment (Supplementary file 2).

Figure 5. Conditional *HLA* association analysis. Upper panel: *HLA* association analysis for blood
donorship. Middle panel: *HLA* association analysis for blood donorship adjusted with rs9272324.
Lower panel: *HLA* association analysis for blood donorship adjusted with *HLA-DRB1**04:01.
Covariates used in all the analysis: age, sex, BMI, PC1-10, birth region and FinnGen genotyping array
version. Dotted horizontal line corresponds to the highest p-value that still fits the FDR limit of 0.05.

Variants altering protein expression levels

To investigate the function of the lead GWAS variants more closely, we employed protein

quantitative trait loci (pQTL) and functional enrichment analyses. Of the 41 fine-mapped and five

MHC region variants, 14 were found to be significantly associated (FDR <0.05) with 81 unique plasma

protein expression levels (Table 2). Most of the associations, comprising 63 unique proteins, were

found with rs687621 located in the *ABO* gene. These included genes that encode for proteins

fundamental to the histo-blood group ABO formation, such as *ABO* antigens and *FUT1*. The latter is

needed in the fucosylation of the precursor *H* antigen in the ABO biosynthesis[28]. Decreasing effects

on expression were seen for e.g. *FUT1*, *VWF*, *F8* and *CLEC4M*, and increasing effects for *ALPI* and

SELE. Importantly, rs55794721 exerted a decreasing effect on *ICAM4*, a gene encoding for LW

glycoprotein present in the RhD protein complex (Figure 6). In addition, two variants were

associated with protein expression levels of genes putatively associated with carcinogenesis (Figure

6). rs12539059 regulates protein levels of *KLK11*, a kallikrein suspected to play a role in

carcinogenesis in human tissues[29]. Another putatively cancer-related[28] protein association was seen

for rs60678519 and *GPNMB*. Overexpression of GPNMB has been shown to lead into

immunosuppression within tumor immune microenvironment and further into poorer prognosis in

variety of cancers[30].

The STRING[31] functional enrichment analysis tool identified several functional processes (PPI

enrichment p-value < 1 x 10^{-16}) among the 81 proteins. Gene Ontology (GO) revealed the enrichment

of cell adhesion molecules in biological processes and molecular functions. These molecules were

further refined to ICAM, C-type lectin and immunoglobulins in protein domains. Other functional

categories were blood groups, hemoglobin and iron metabolism, immunology, and cell-cell adhesion

(Supplementary file 3).

We detected three associations with protein expression level alteration that weren't involved with

any of the enriched biological or cellular processes (Supplementary file 3). rs113236240 showed an

increasing effect (beta = 0.36) on *PPCDC*, encoding for a protein needed in coentzyme A

biosynthesis[28]. rs687621 showed a decreasing effect (beta = -0.4) on *GOLM2*, a proto-oncogene

whose overexpression associates with proto-oncogene *HER2/neu*, found in human breast and

ovarian cancers[28]. rs1135071 showed a strong increasing effect (beta 2.57) on *AHSP* (Figure 6), which

encodes for chaperone protein binding free alpha-globin and therefore having a stabilizing effect in

hemoglobin assembly[28].

Figure 6 Association of the variants to protein expression level alteration. Six variants with
association to protein level alteration in pQTL analysis are shown in the figure. The lead variant in
ABO gene rs687621, was found to be associated to 63 unique protein level alterations. Lead variant
in MHC region in unadjusted GWAS, rs9272324, showed association mainly to immunity related
protein level alteration. Variants with decreasing effect on hemoglobin level (Supplementary file 2)
rs199598395 and rs1135071 showed association to iron metabolism genes and hemoglobin related
gene, respectively. rs6067859 and rs12539059 showed increasing effect on expression of putative
cancer-related genes. Variants are annotated if they were significantly (FDR<0.05) associated with
protein level alteration. All the variants effecting on protein levels can be found in Table 2 and in
more detail in Supplementary file 3.

Putative bias caused by red cell antigen enrichment in research setting

Protective association of red cell antigen O to venous thromboembolism (VTE) has been shown

previously by multiple studies[14–16]. To investigate the putative bias an ABO enrichment could cause

to VTE association study, we conducted an association analysis with VTE as an endpoint in

chromosome 9 (Supplementary Figure 3A) by adjusting for imputed ABO antigens (Supplementary

Figure 3). Our results showed that after the adjustment, the p-value of the lead variant failed to

reach the genome-wide significance level 5×10^{-8} (rs582118 unadjusted p = 3.28×10^{-115}, ABO

adjusted p = 1.16×10^{-6}) but the signal was not completely removed as some genome-wide

significant variants still remained (Supplementary Figure 3A-B). The adjustment not only removed

associations of some SNPs but also made visible other variants not detected in the basic analysis

(Supplementary Figure 3C).

Discussion

In the present study we conducted a genome-wide comparison between blood donor biobank

donors with relatively long and active blood donation history[17] and FinnGen. The FinnGen control

population included individuals from hospital biobanks, population cohorts, and patients at

occupational health clinics. As the latter two cohorts comprise largely healthy individuals, and the

disease-specific legacy cohorts were excluded from the analysis, the study controls are likely

representative of the general Finnish population.

The observed protection of blood donors from certain diseases can be directly attributed to donor

eligibility criteria that select healthy individuals. However, some of the observed protective genetic

factors maybe secondary. For instance, strong negative correlation with anaemia in blood donors

could be due to the absence of certain autoimmune diseases, such as Crohn's disease, which can

cause anaemia through secondary blood loss. Surprisingly, our results reveal that blood donors not

only exhibit a protective genetic profile against diseases explicitly targeted by donor eligibility

criteria, but also show a broader negative genetic correlation with conditions beyond these criteria,

including various mental illnesses, infectious diseases and Alzheimer's disease. While pleiotropic

effects may explain this phenomenon, our analyses indicate that the genetic correlation with the

phenotypes targeted by the eligibility criteria is not consistently strong. Further detailed

investigations are required to fully understand pleiotropy in blood donor selection and to explore

the potential benefits of an active blood donor population for genetic and biomedical research.

Expectedly, genetic variants in the MHC region played strong role in several genetic associations as

well as in genetic correlation. HLA alleles with known autoimmune associations occurred with lower

frequency in the blood donor population than in the control population, whereas hemochromatosis

related HLA alleles[17] and HLA alleles with known protective role in autoimmunity, were more

frequent among the blood donors.

In addition to tagging certain autoimmune-related HLA-alleles or -haplotypes (e.g T1D and

ankylosing spondylitis), rs9272324 was shown to enhance the protein levels of *HLA-DRA*, which

encodes the nonpolymorphic *DR* alpha-chain[32] essential for the stable expression of DR molecules on

the cell surface. Considering this, the known associations of *HLA-DRB1*15:01* in multiple

sclerosis[6,33] and the lower frequency of the rs9272324 in blood donors, further investigation of the

role of rs9272324 in multiple sclerosis and in autoimmunity in general would be of interest.

Furthermore, the significantly higher frequency of rs9968910 and rs9272324 among individuals with

clinical hemochromatosis could shed light on the long-discussed low penetrance of the well-

described *HFE* variants *C282Y* and *H63D* in clinical hemochromatosis[34].

In biomedical research, active blood donors present valuable opportunities due to their positive

attitude toward research, availability for longitudinal sampling, and unique genetic makeup.

However, when using blood donors exclusively as a control group, it is essential to critically evaluate

and interpret the results. The strong immunogenicity of certain blood group antigens,[10–13] as well as

the constant need for emergency blood (O RhD neg), leads to the enrichment of these red cell

antigens in the blood donor population, as demonstrated in this study.

Multiple studies have shown a relationship between the ABO blood group and cardiovascular

conditions, specifically noting the decreased risk of thromboembolic events in individuals with blood

group O[15,35]. In research settings where blood donors are used as a healthy control population,

confounding factors, such as the enrichment of blood group O, should be taken into consideration,

as demonstrated by our VTE association analysis.

Furthermore, blood group antigen related variants rs55794721 and rs687621 were found to

decrease the expression level of genes involved in the function or structure of the cognate blood

group molecules. These include the RhD accessory protein ICAM4, the Landsteiner-Wiener

glycoprotein[11], and FUT1, a fucosyltransferase necessary in the conversion of the *H* antigen in ABO

biosynthesis[16,28,36,37]. The variant rs687621 alone altered expression levels of 63 genes, whose

products are involved in various biological pathways. Due to the enrichment of blood group O in the

blood donor pool, there was a decreasing effect on proteins involved in hemostasis and thrombosis,

such as VWF and F8.

Conversely, an increase in protein levels associated with rs687621 was observed for ALPI and SELE.

ALPI plays a role in the defense system of the gut mucosal and is thought to prevent bacterial

translocation, while SELE is speculated to have role in atherosclerosis. Both of these immunity and

cardiovascular related functions are well-known roles of ABO blood group

antigens[14,15,36,38].Additionally, another significant finding was the variant rs55794721, which was

shown to tag the most frequent RhD negative haplotype in individuals of European ancestry, Rh dce.

In addition to hemochromatosis, the results of the present study highlight genetic factors that may

affect recipient matching or donation activity. We show a lower expression level of AHSP protein in

blood donors due to the lower frequency of rs1135071, which was also shown to decrease the

hemoglobin level in this study. Consequently, blood donors exhibited higher hemoglobin levels.

AHSP plays a crucial role in hemoglobin assembly by stabilizing the αHb subunits and preventing the

self-aggregation of excess αHb subunits prior the formation of HbA1 subunit[39]. To our knowledge, no

earlier studies have indicated an increasing effect of *Hb Tacoma* variant rs1135071 on AHSP levels.

Given the speculated role of AHSP as a genetic modifier in β-thalassemia[39,40] and the described

normal clinical phenotype of *Hb Tacoma* heterozygotes[41], rs1135071 could be of further interest in

β-thalassemia research.

Furthermore, regarding donor health, it may be useful to analyze whether blood donation is

harmless for *Hb Tacoma* heterozygotes or whether the blood products are suitable for recipients

with conditions such as sickle cell disease[42]. The known association of rs199598395 with iron

deficiency[18], its effect on blood donation eligibility,[23] and the decreasing effect on hemoglobin levels

demonstrated in this study support the need for further evaluation of its role in blood donation

eligibility or interval.

In this study we present, to our knowledge for the first time, the genetic underpinnings of HDE and

blood group-based selection in active blood donors. Our findings highlight the unique genetic

makeup of this donor population and its impact on health and blood donation suitability. The results

demonstrate the role of genetics in maintaining good health status and active blood donation career

that is also connected to a better mental health at the genetic level. Furthermore, research using

blood donors as a control group should account for this distinct genetic structure, even after

donation ceases. Additionally, the enrichment of specific blood group antigens among blood donors

warrants consideration in research as these antigens carry several known disease associations.

Further investigations are necessary to fully elucidate the implications of these discoveries, but they

underscore the genetic structure behind HDE and the potential of active blood donor cohorts for

advancing biomedical genetic research.

Material and Methods

Ethics statement

Study subjects in FinnGen provided informed consent for biobank research, based on the Finnish

Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish Biobank Act came

into effect (in September 2013) and start of FinnGen (August 2017), were collected based on study-

specific consents and later transferred to the Finnish biobanks after approval by Fimea (Finnish

Medicines Agency), the National Supervisory Authority for Welfare and Health. Recruitment

protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of

the Hospital District of Helsinki and Uusimaa (HUS) statement number for the FinnGen study is Nr

HUS/990/2017. Full list of permits numbers are listed in Supplementary information.

All the sample donors had given a written biobank consent. The use of the data in the present study

is in accordance with the biobank consent and meets the requirements of the Finnish Biobank Act

688/2012. A formal biobank decision 004-2022 for the research project has been granted by the

Finnish Red Cross Blood Service Biobank. The use of the FinnGen data has been accepted with

FinnGen proposal F_2022_086.

Data acquisition

Genome data used in the present study originated from samples that were genotyped in the

FinnGen project with the FinnGen ThermoFisher Axiom custom array v1 or v2 and genome

imputation version R12. Genotyping, quality control, and genome imputation protocols are

described in detail in FinnGen Gitbook[43]. In short, genotype calling was performed with GenCall or

zCall algorithm for Illumina and AxiomGT1 algorithm for Affymetrix arrays. Prior the imputation,

genotyped samples were pre-phased with Eagle 2.3.5 with the default parameters, except the

number of conditioning haplotypes was set to 20,000. Genotype imputation was performed using

the population-specific imputation reference panel SISu v4.2 with Beagle 4.1 (version 27Jan18.7e1).

In addition to genome data, the following electronic health registry data and supplementing data

were utilized: ICD (ICD9 and 10) code for type 1 diabetes, occurrence of venous thromboembolism,

age, BMI, sex, region of birth and genetic principal components (PC) 1-10. Blood donation data

contained blood donation history and hemoglobin value measured at the point of each blood

donation event and was used when applicable. Donors with three or less donation events were

filtered from the hemoglobin analyses. Blood donation data was available from 44,675 donors.

Due to the known selection of healthy individuals as blood donors, legacy samples[43], highly enriched

in certain common diseases, were filtered out from the study cohort to minimize possible bias in

downstream analyses. Individuals under 18 years of age were removed as 18 is the age limit of blood

donation. In addition, individuals born in regions in Finland that were ceded to Soviet Union were

filtered out due to age structure of the region and the maximum blood donation age of 70 years. As

BMI might influence donor eligibility, individuals lacking BMI information were filtered out. After

filtering, total number of FinnGen genome data used in this study was 53,688 cases (blood donors)

and 228,060 controls (other FinnGen participants).

Methods

Statistical analyses

If not stated otherwise, all statistical analyses were performed in R[44] version 4.3 or 4.4, with

RStudio[45]. The genome-wide significance p-value threshold $p < 5 \times 10^{-8}$ was used in GWAS. In all

other analyses p-values were adjusted with the Benjamini–Yekutieli procedure[46], and significance

threshold of 0.05 was used. All the phenotypes described here, have been previously studied and

described in FinnGen in DF12 dataset. At the present, only DF10 data set is publicly available[18].

Association analysis and fine-mapping

Genome-wide association study, GWAS, with an additive genetic model, was performed in FinnGen

pipeline with Regenie[47,48] v2.2.4 with blood donor status as a binary endpoint. Sex, age, BMI, PC1-10,

birth region, and FinnGen genotyping array version were used as covariates in the GWAS. To

discover associations independent of type 1 diabetes (T1D) in chromosome 6, the FinnGen T1D

endpoint [22] was used as an additional covariate in the chromosome 6 association analysis.

Fine-mapping for the genome wide significant signals ($p < 5 \times 10^{-8}$) of the association study was

performed in FinnGen pipeline[48] with SuSiE[49] excluding MHC region (GRCh38, chr6:25-34 Mb)[22,43].

For each fine-mapped locus we accepted the credible set as an independent hit if the strongest

primary p-value was $p < 5 \times 10^{-8}$. In case of multiple credible sets within a single locus, to accept the

secondary hit, we required genome-wide significance and $\log_{10}$(Bayes factor) > 2. As the MHC region

is excluded from the fine-mapping pipeline due to its strong LD, the lead variants from the T1D

adjusted association analysis, rs9968910, rs10947114, rs3130906 and rs4713637, were selected for

the downstream analysis. Moreover, the lead variant in the MHC region in GWAS, rs9272324, was

included in the further analyses due to its strong association in autoimmunity[18] and the

hypothesized lower association with autoimmunity among blood donors.

Association analysis for all the covariates used in GWAS and the imputed blood groups to the blood

donor end point was performed with logistic regression in R. We further analyzed the association of

all the covariates used in GWAS and imputed blood group antigens to the lead variants in dosage

form in chromosomes 1 (rs55794721), 7 (rs8176058) and 9 (rs687621) by using linear regression.

Association testing of each classical *HLA* allele *HLA-A, -B, -C, -DRB1, -DQA1, -DQB1, DPB1* and *HLA-*

DRB3-5 for the blood donor endpoint was performed using Regenie v3.0.1. First, a genotype data set

for fitting Regenie null models was formed with Plink2 v2.00a4LM using FinnGen DF12 HapMap3

variants as a basis and randomly thinning the variants to 500 000 with further filtering for minor

allele frequency at least 0.1, Hardy-Weinberg equilibrium greater than p-value 1e-15 and minimum

allele count at least 100. Second, the Regenie null models were fitted on the filtered genotype data

and used in the association step to take consanguinity into account. To dissect the HLA signal

further, two additional association tests were performed: i) conditioning for GWAS chromosome 6

lead variant rs9272324 allele and ii) conditioning for the HLA allele dosage with the strongest

association, *HLA-DRB1*04:01*, in the primary HLA association analysis.

To understand the putative bias caused by red cell antigen, ABO, enrichment in the blood donor

pool, we conducted an association study in chromosome 9 in FinnGen pipeline with Regenie[47,48]

v2.2.4 with FinnGen venous thromboembolism[22] as a binary endpoint. Sex, age, PC1-10, FinnGen

genotyping array version, and FinnGen batch information were used as covariates. In the primary

analysis there were 19,957 cases and 344,672 controls. The primary analysis was conditioned with

imputed ABO red cell antigens. After filtering out 20 individuals based on low posterior probability of

the imputed ABO antigens, 19,956 cases and 344,653 controls remained in the conditional analysis.

Genetic correlation

All pair-wise genetic correlations between blood donorship, hemoglobin and all the 2470

phenotypes previously studied as part of FinnGen study were computed using LD Score Regression

v1.0.1 using Finnish LD panel in FinnGen pipeline[48]. The computation was based on the GWAS

summary statistics previously obtained using Regenie for each phenotype. We used the Benjamini-

Yekutieli method to control FDR of genetic correlation at level 0.05. Genetic correlation between

groups of phenotypes was approximated as the average of all the pair-wise genetic correlations

between the groups.

HLA and blood group imputation

The alleles of the classical HLA genes, *HLA-A, -C, -B, -DRB1, DRB3-5, -DQA1, -DQB1,* and *-DPB1*, had

been previously imputed at four-field resolution (i.e., defining protein sequence variation) in

FinnGen using HIBAG[50] algorithm with population-specific refence panel as reported earlier[51]. The

dosage value of each HLA-allele was used in downstream analyses. Altogether 37 Red Blood cell,

RBC, antigens in 14 different blood group systems were imputed using random forest models as

described by Hyvärinen et al[52]. After imputation, *P1, A1* and *A2* antigens were excluded from

downstream analyses due to uncertain frequency at the population level. In addition, blood group

antigens *HrS* and *HrB*, occurring mainly in African population, are in high correlation with blood

group antigen *e* and have low clinical significance (consultation with expert at Finnish Red Cross

Blood Service), hence they were excluded from further analyses. After imputation, the samples were

filtered based on the posterior probability, PP, value; samples with PP < 0.5 were considered as

antigen negative and samples with PP ≥ 0.5 were considered as antigen positive. Altogether 13

individuals were excluded from downstream blood group related analyses due to all PP values in

ABO being < 0.5.

pQTL

Protein quantitative trait loci, pQTL, analysis had been previously performed in FinnGen[48,53] with

multiplex antibody-based immunoassay and multiplex aptamer-based immunoassay, Olink and

SomaScan[54], respectively, to detect associations between genetic variants and measured protein

levels. We extracted the proteomics summary statistics data for the 41 fine-mapped and the five

MHC lead variants in the present study from both datasets, Olink and SomaScan, and filtered the

results for statistical significance at FDR < 0.05 level.

To evaluate the enrichment of the associated proteins in functional processes, we used STRING

interaction network and functional enrichment analysis tool[31].

Data Availability

FinnGen summary statistics are available at www.finngen.fi. Data supporting the current study are

available from the authors upon reasonable request and with permission of FinnGen.

The GWAS results for the blood donor phenotype are available at GWAS catalogue under accession

number XXXXX.

Code Availability

Code is available in GitHub XXXXXX

References

1.   Mitchell, R. Blood banks, biobanks, and the ethics of donation. *Transfusion* **50**, 1866–1869
(2010).

2.   Raivola, V., Snell, K., Helén, I. & Partanen, J. Attitudes of blood donors to their sample and
data donation for biobanking. *Eur. J. Hum. Genet.* **27**, 1659–1667 (2019).

3.   Raivola, V., Snell, K., Helen, I. & Partanen, J. Attitudes of blood donors to their sample and
data donation for biobanking. *Eur. J. Hum. Genet.* **27**, 1659–1667 (2019).

4.   Finnish Red Cross Blood Service - donation eligibility.
https://www.veripalvelu.fi/en/faq/?search=&category=eligibility.

5.   Hu, X. *et al.* Additive and interaction effects at three amino acid positions in HLA-DQ and
HLA-DR molecules drive type 1 diabetes risk. *Nat. Genet.* **47**, 898–905 (2015).

6.   De Silvestri, A. *et al.* The Involvement of HLA Class II Alleles in Multiple Sclerosis: A Systematic
Review with Meta-analysis. *Dis. Markers* **2019**, 1409069 (2019).

7.   Dendrou, C. A., Petersen, J., Rossjohn, J. & Fugger, L. HLA variation and disease. *Nat. Rev.*
Immunol. **18**, 325–339 (2018).

8.   Ritari, J., Koskela, S., Hyvärinen, K., FinnGen & Partanen, J. HLA-disease association and
pleiotropy landscape in over 235,000 Finns. *Hum. Immunol.* **83**, 391–398 (2022).

9.   Atsma, F., Veldhuizen, I., Kort, W. De & Vegt, F. De. Healthy donor effect: its magnitude in
health research among blood donors. *Transfusion* **51**, 1820–1828 (2011).

10.   Marsh, W. L. & Redman, C. M. The Kell blood group system: a review. *Transfusion* **30**, 158–
167 (1990).

11.   Avent, N. D. & Reid, M. E. The Rh blood group system: a review. *Blood* **95**, 375–387 (2000).

12.   Levine, P. & Stetson, R. E. Landmark article July 8, 1939. An unusual case of intra-group
agglutination. By Philip Levine and Rufus E Stetson. *JAMA* **251**, 1316–1317 (1984).

13.   GIBLETT, E. R. A critique of the theoretical hazard of inter vs. intra-racial transfusion.
Transfusion **1**, 233–238 (1961).

14.   Stowell, S. R. & Stowell, C. P. Biologic roles of the ABH and Lewis histo-blood group antigens
part II: thrombosis, cardiovascular disease and metabolism. *Vox Sang.* **114**, 535–552 (2019).

15.   Dahlén, T., Clements, M., Zhao, J., Olsson, M. L. & Edgren, G. An agnostic study of associations
between ABO and RhD blood group and phenome-wide disease risk. *Elife* **10**, (2021).

16.   Ward, S. E., O'Sullivan, J. M. & O'Donnell, J. S. The relationship between ABO blood group,
von Willebrand factor, and primary hemostasis. *Blood* **136**, 2864–2874 (2020).

17.   Clancy, J. *et al.* Blood donor biobank as a resource in personalised biomedical genetic
research. *Eur. J. Hum. Genet.* (2024) doi:10.1038/s41431-023-01528-0.

18.   FinnGen. FinnGen Result Browser. https://r10.finngen.fi/ (2024).

19.   National Institutes of Health LDlink. https://ldlink.nih.gov/?tab=home.

20.   ISBT Blood Group Allele Tables. https://www.isbtweb.org/isbt-working-parties/rcibgt/blood-
599   group-allele-tables.html.

600   21.   Li, S. & Schooling, C. M. A phenome-wide association study of ABO blood groups. *BMC Med.*
601   **18**, 334 (2020).

602   22.   Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated
603   population. *Nature* **613**, 508–518 (2023).

604   23.   Toivonen, J., Allara, E., Castrén, J., di Angelantonio, E. & Arvas, M. The value of genetic data
605   from 665,460 individuals in managing iron deficiency anaemia and suitability to donate
606   blood. *Vox Sang.* **119**, 34–42 (2024).

607   24.   Kangastupa, P. *et al.* The prevalence of hemoglobin Tacoma in Finland detected by HbA1c
608   capillary electrophoresis. *Scand. J. Clin. Lab. Invest.* **83**, 51–57 (2023).

609   25.   Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in
610   141,456 humans. *Nature* **581**, 434–443 (2020).

611   26.   Bowness, P. HLA-B27. *Annu. Rev. Immunol.* **33**, 29–48 (2015).

612   27.   Simmons, K. M. *et al.* Failed Genetic Protection: Type 1 Diabetes in the Presence of HLA-
613   DQB1*06:02. *Diabetes* **69**, 1763–1769 (2020).

614   28.   Sayers, E. W. *et al.* Database resources of the national center for biotechnology information.
615   *Nucleic Acids Res.* **50**, D20–D26 (2022).

616   29.   Borgoño, C. A., Michael, I. P. & Diamandis, E. P. Human tissue kallikreins: physiologic roles
617   and applications in cancer. *Mol. Cancer Res.* **2**, 257–280 (2004).

618   30.   Lazaratos, A.-M., Annis, M. G. & Siegel, P. M. GPNMB: a potent inducer of
619   immunosuppression in cancer. *Oncogene* **41**, 4573–4590 (2022).

620   31.   Szklarczyk, D. *et al.* The STRING database in 2023: protein-protein association networks and
621   functional enrichment analyses for any sequenced genome of interest. *Nucleic Acids Res.* **51**,
622   D638–D646 (2023).

623   32.   Brown, J. H. *et al.* Three-dimensional structure of the human class II histocompatibility
624   antigen HLA-DR1. *Nature* **364**, 33–39 (1993).

625   33.   Goodin, D. S., Khankhanian, P., Gourraud, P.-A. & Vince, N. Highly conserved extended
626   haplotypes of the major histocompatibility complex and their relationship to multiple
627   sclerosis susceptibility. *PLoS One* **13**, e0190043 (2018).

628   34.   Miller, D. T. *et al.* ACMG SF v3.0 list for reporting of secondary findings in clinical exome and
629   genome sequencing: a policy statement of the American College of Medical Genetics and
630   Genomics (ACMG). *Genet. Med.* **23**, 1381–1390 (2021).

631   35.   Groot, H. E. *et al.* Genetically Determined ABO Blood Group and its Associations With Health
632   and Disease. *Arterioscler. Thromb. Vasc. Biol.* **40**, 830–838 (2020).

633   36.   Stowell, C. P. & Stowell, S. R. Biologic roles of the ABH and Lewis histo-blood group antigens
634   Part I: infection and immunity. *Vox Sang.* **114**, 426–442 (2019).

37.   Daniels, G. The molecular genetics of blood group polymorphism. *Hum. Genet.* **126**, 729–742

(2009).

38.   Franchini, M., Favaloro, E. J., Targher, G. & Lippi, G. ABO blood group, hypercoagulability, and
cardiovascular and cancer risk. *Crit. Rev. Clin. Lab. Sci.* **49**, 137–149 (2012).

39.   Che Yaacob, N. S., Islam, M. A., Alsaleh, H., Ibrahim, I. K. & Hassan, R. Alpha-hemoglobin-
stabilizing protein (AHSP): a modulatory factor in β-thalassemia. *Int. J. Hematol.* **111**, 352–
359 (2020).

40.   dos Santos, C. O. & Costa, F. F. AHSP and beta-thalassemia: a possible genetic modifier.
Hematology **10**, 157–161 (2005).

41.   Giardine, B. *et al.* Updates of the HbVar database of human hemoglobin variants and
thalassemia mutations. *Nucleic Acids Res.* **42**, D1063-9 (2014).

42.   Rutherford-Parker, N. J., Colby, J. M., Gehrie, E. A. & Booth, G. S. Unrecognized Hemoglobin
Variants in the Donor Blood Supply Are Detectable in the Transfused Population. *Am. J. Clin.*
Pathol. **154**, 494–498 (2020).

43.   FinnGen. FinnGen Documentation of data release.
https://finngen.gitbook.io/documentation/ (2024).

44.   R Core Team. https://www.r-project.org/.

45.   R studio. https://www.rstudio.com/.

46.   Benjamini, Y. & Yekutieli, D. The control of the false discovery rate in multiple testing under
dependency. *Ann. Stat.* **29**, 1165–1188 (2001).

47.   Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and
binary traits. *Nat. Genet.* **53**, 1097–1103 (2021).

48.   FinnGen gitbook. https://github.com/FINNGEN/.

49.   Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A Simple New Approach to Variable
Selection in Regression, with Application to Genetic Fine Mapping. *J. R. Stat. Soc. Ser. B Stat.*
Methodol. **82**, 1273–1300 (2020).

50.   Zheng, X. *et al.* HIBAG - HLA genotype imputation with attribute bagging. *Pharmacogenomics*
J. **14**, 192–200 (2014).

51.   Ritari, J. *et al.* Increasing accuracy of HLA imputation by a population-specific reference panel
in a FinnGen biobank cohort. *NAR Genomics Bioinforma.* **2**, (2020).

52.   Hyvärinen, K. *et al.* A machine-learning method for biobank-scale genetic prediction of blood
group antigens. *PLoS Comput. Biol.* **20**, e1011977 (2024).

53.   FinnGen. FinnGen Documentation. https://finngen.gitbook.io/finngen-handbook (2024).

54.   Suhre, K., McCarthy, M. I. & Schwenk, J. M. Genetics meets proteomics: perspectives for large
population-based studies. *Nat. Rev. Genet.* **22**, 19–37 (2021).

Acknowledgements:

We want to acknowledge the participants and investigators of FinnGen study. The FinnGen project is

funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the

following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb

(and Celgene Corporation & Celgene International II Sàrl), Genentech Inc., Merck Sharp & Dohme

LCC, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc.,

Maze Therapeutics Inc., Janssen Biotech Inc, Novartis Pharma AG, and Boehringer Ingelheim

International GmbH. Following biobanks are acknowledged for delivering biobank samples to

FinnGen: Auria Biobank (www.auria.fi/biopankki), THL Biobank (www.thl.fi/biobank), Helsinki

Biobank (www.helsinginbiopankki.fi), Biobank Borealis of Northern Finland

(https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-

English.aspx), Finnish Clinical Biobank Tampere (www.tays.fi/en-

US/Research_and_development/Finnish_Clinical_Biobank_Tampere), Biobank of Eastern Finland

(www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-FI/Potilaalle/Biopankki),

Finnish Red Cross Blood Service Biobank (www.veripalvelu.fi/verenluovutus/biopankkitoiminta),

Terveystalo Biobank (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/) and

Arctic Biobank (https://www.oulu.fi/en/university/faculties-and-units/faculty-medicine/northern-

finland-birth-cohorts-and-arctic-biobank). All Finnish Biobanks are members of BBMRI.fi

infrastructure (www.bbmri.fi). Finnish Biobank Cooperative -FINBB (https://finbb.fi/) is the

coordinator of BBMRI-ERIC operations in Finland. The Finnish biobank data can be accessed through

the Fingenious® services (https://site.fingenious.fi/en/) managed by FINBB.

In addition, we want to acknowledge Dr Katri Haimila for her valuable advice with red cell antigen

immunogenetics, Dr Kati Hyvärinen for her expertise and kind help with red cell antigen imputation

and the personnel of Blood Service Biobank for their kind help and support for the study.

Author Contributions

Original study concept by JC and JR. Genetic and statistical analysis of the study: JC, JT, MA and JR.

Visualization: JC, JT and JR. Medical expertise: JL. FinnGen: data curation and resources. Procedures

in the Blood Service Biobank: SK. Original manuscript: JC. JC, JT, JL, SK, JP, FinnGen, MA, JR read,

commented, and approved the final manuscript.

Competing Interests

The authors declare no competing interests.